Strategic Collaboration Aims to Discover and Develop Potentially
Novel Antibodies Against Specified Targets for Immunotherapy
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) today announced that it
has entered into a Collaborative Research and Development Agreement with
The University of Texas MD Anderson Cancer Center.
Scientists from Enumeral and MD Anderson will collaborate on the
discovery and development of novel monoclonal antibodies against
specified targets in immuno-oncology, leveraging Enumeral’s antibody
discovery and patient-centric immune profiling platform and MD
Anderson’s preclinical and development expertise and infrastructure.
Under the terms of the agreement, Enumeral and MD Anderson will share
the costs of such research and development activities, and will each be
granted the right to receive a percentage of the net income from product
sales or any payments associated with licensing or otherwise partnering
a program with a third party.
“This strategic collaboration leverages the considerable experience of
MD Anderson in translational medicine and clinical oncology and
Enumeral’s core strengths of antibody discovery and patient-centric
functional immune profiling," said Arthur H. Tinkelenberg, Ph.D.,
Enumeral’s President and Chief Executive Officer. “With our platform’s
ability to measure the effects of novel antibody candidates on human
lymphocyte function in tumor biopsy samples from patients, and MD
Anderson’s deep expertise and infrastructure for preclinical and
clinical oncology product development, we believe working with MD
Anderson and their Oncology Research for Biologics and Immunotherapy
Translation (ORBIT) team is an ideal way to accelerate the discovery and
development of novel antibody therapies which may increase the rates of
response and provide for more durable outcomes in the treatment of
cancer.”
ORBIT is a translational research platform of MD Anderson’s Moon Shots
Program, which aims to accelerate the conversion of scientific knowledge
into clinical advances that reduce cancer deaths.
"With its team of industry-seasoned scientists embedded in a top-notch
cancer center, ORBIT was launched to establish this type of
collaborations,” said Carlo Toniatti, M.D., Ph.D., executive director of
ORBIT. “Successful development of novel anti-cancer antibodies requires
faultless integration of drug development expertise, deep biological
knowledge and clinical development capabilities. We are confident that
through this collaboration we will accelerate the delivery of innovative
and efficacious therapies to our patients.”
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel
antibody immunotherapies that help the immune system fight cancer and
other diseases. The Company is building a pipeline focused on
next-generation checkpoint modulators, with initial targets including
PD-1, TIM-3, LAG-3, TIGIT, VISTA, and others. In developing these
agents, Enumeral’s researchers apply a proprietary immune profiling
technology platform that measures functioning of the human immune system
at the level of individual cells, providing key insights for candidate
selection and validation. For more information on Enumeral, please visit www.enumeral.com.
About MD Anderson
The
University of Texas MD Anderson Cancer Center in Houston ranks as
one of the world's most respected centers focused on cancer patient
care, research, education and prevention. The institution’s sole mission
is to end cancer for patients and their families around the world. MD
Anderson is one of only 45 comprehensive cancer centers designated by
the National Cancer Institute (NCI). MD Anderson is ranked No.1 for
cancer care in U.S. News & World Report’s “Best Hospital’s” survey. It
has ranked as one of the nation’s top two hospitals since the survey
began in 1990, and has ranked first for 11 of the past 14 years. MD
Anderson receives a cancer center support grant from the NCI of the
National Institutes of Health (P30 CA016672).
Forward Looking Statements Disclosure
This press release contains certain “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995, as
amended. Such statements reflect current beliefs of Enumeral Biomedical
Holdings, Inc. (“Enumeral”) with respect to future events and involve
known and unknown risks, uncertainties, and other factors affecting
operations, market growth, Enumeral’s stock price, services, products
and licenses. No assurances can be given regarding the achievement of
future results, and although Enumeral believes that the expectations
reflected in these forward-looking statements are based on reasonable
assumptions, actual results may differ from the assumptions underlying
the statements that have been made regarding anticipated events. Factors
that may cause actual results, performance or achievements, or industry
results to differ materially from those contemplated by such
forward-looking statements include, among others, the risks that (a)
Enumeral’s expectations regarding market acceptance of the Company’s
business in general and the Company’s ability to penetrate the antibody
discovery and development fields in particular, as well as the timing of
such acceptance, (b) Enumeral’s ability to attract and retain management
with experience in biotechnology and antibody discovery and similar
emerging technologies, (c) the scope, validity and enforceability of
Enumeral’s and third party intellectual property rights, (d) Enumeral’s
ability to raise capital when needed and on acceptable terms and
conditions, (e) Enumeral’s ability to comply with governmental
regulation, (f) the intensity of competition, (g) changes in the
political and regulatory environment and in business and fiscal
conditions in the United States and overseas and (h) general economic
conditions.
More detailed information about Enumeral and risk factors that may
affect the realization of forward-looking statements, including
forward-looking statements in this press release, is set forth in
Enumeral’s filings with the Securities and Exchange Commission. Enumeral
urges investors and security holders to read those documents free of
charge at the Commission’s website at http://www.sec.gov.
Forward-looking statements speak only as to the date they are made, and
except for any obligation under the U.S. federal securities laws,
Enumeral undertakes no obligation to publicly update any forward-looking
statement as a result of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160111005312/en/
Copyright Business Wire 2016